drugset / Trial / NCT05950334
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
Timeline
- Start
- 2023-11-16
- Primary completion
- 2025-06-06
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FT522 | Unknown | — | Intravenous |
| Background | Bendamustine | Small molecule | 90 mg/m2 | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |